NewLead Holdings Ltd (NASDAQ:NEWL) & Curis Inc (NASDAQ:CRIS) trade in negative territory
NewLead Holdings Ltd (NASDAQ:NEWL): In Tuesday’s trading session, NewLead Holdings Ltd (NASDAQ:NEWL) dipped 1.58%. Its opening price of $0.26 rose to touch an intraday high of $0.28 which eventually headed down to currently trade at $0.261 per share. Over 1.74 million shares exchanged hands in the current trading session. This number stood above the average volume of 0.824 million that was measured over a 30-day period.
NEWL is an international shipping company. It is engaged in transporting refined products such as jet fuel and gasoline. It also transports dry bulk goods such as iron ore, grain and coal. NewLead Holdings Ltd (NASDAQ:NEWL) operates in two different segments- The first is wet operations. This segment consists of tankers that are involved in the transportation of various refined petroleum products. The second segment deals in segregated dry operations and coated cargo tanks. These include the transportation and handling of various bulk cargoes. This could be via ownership, operation as well as trading of vessels. It operates a fleet of two, double-hulled product-tankers and 3 drybulk carriers (including one new-building). These have a combined carrying-capacity of around 0.39 million deadweight tonnage.
Curis, Inc (NASDAQ:CRIS): In Tuesday’s trading session, Curis, Inc (NASDAQ:CRIS) dipped 0.51%. Its opening price of $3.91 rose to touch an intraday high of $3.97 which eventually headed down to currently trade at $3.89 per share. Over 0.265 million shares exchanged hands in the current trading session. This number stood below the average volume of 0.767 million that was measured over a 30-day period.
CRIS is a drug discovery and development company. It is committed to leveraging signaling of pathway drug technologies. It seeks to develop next generation network-targeted therapies that are used in the treatment of cancer. Its research and development programs are conducted internally as well as via strategic collaborations. Its advanced program, the Hedgehog pathway inhibitor program is conducted in collaboration with Genentech, Inc. The latter is a wholly-owned member of the Roche Group. Erivedge is the lead drug candidate that is being developed under this program. It is an orally-administered small molecule pathway inhibitor and is also known as vismodegib, RG3616 and GDC-0449. In 2011 October it completed a Phase Ib expansion trial for testing CUDC-101.